NCT03199586已完成1 期
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 3
- 主要终点
- Establish the safe recommended phase 2 dose
研究概览
简要总结
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent and mental capability to understand the informed consent
- •Male or female patients > 18 years of age
- •Histologically or cytologically documented locally advanced or metastatic solid tumor malignancies either treatment-refractory or otherwise ineligible for treatment with standard-of-care agents/regimens
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- •Evaluable or measurable disease per RECIST v1.1
- •Life expectancy > 3 months
- •ECG without evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the Investigator
- •Acceptable organ and marrow function as defined below:
- •Absolute neutrophil count > 1,500 cells/μL
- •Hemoglobin ≥ 9.0 g/dL
- •Platelets > 100,000 cells/μL
- •Total bilirubin ≤ 1.5 mg/dL
- •Albumin ≥ 3 g/dL
- •Aspartate aminotransferase (AST)/alanine transaminase (ALT)/alkaline phosphatase (ALP)/Gamm-glutamyl transferase (GGT) ≤ 2.5 times ULN. For Phase 1A only, if liver metastases are present, AST/ALT/ALP < 5 times ULN
- •Serum creatinine < 1.5 mg./dL and a measured creatinine clearance ≥ 60 mL/min
- •Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times ULN
- •Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test prior to first dose of study drug.
- •Male and female patients with reproductive potential must agree to use adequate contraceptive precautions throughout the study.
排除标准
- •Chemotherapy, radiotherapy or other anti-cancer treatment within 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) of the first dose of study drug or patients who in opinion of Investigator have not recovered from AEs due to agents administered greater than 4 weeks earlier (prior immunotherapy is allowed)
- •Participation in any other clinical investigation using an experimental drug within 4 weeks of first dose of study drug
- •Failure to recover to ≤ grade 1 toxicity (except grade 1-2 alopecia or neuropathy) associated with previous chemotherapy, radiotherapy, biologic, hormone or prior investigational therapy
- •Known untreated brain metastases or treated brain metastases that have not been radiographically and clinically stable (i.e. not requiring steroids) ≥ 4 weeks prior to study enrollment
- •Baseline prolongation of QT/QTc interval (QTc interval > 470 msec in women and >450 msec in men)
- •Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in opinion of Investigator would limit compliance with study requirements
- •Women who are pregnant or breastfeeding
- •Prior allogenic hematopoietic stem cell transplant or allogenic bone marrow transplant or prior solid organ transplant or current use of immuno suppression drugs or anti-transplant rejection drugs
- •Prior history of clinically significant gastrointestinal bleeding, intestinal obstruction or gastrointestinal perforation within 6 months of study enrollment
- •Sponsor reserves right to exclude any patient from the study on basis of pre-study medical histories, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria
研究组 & 干预措施
NP-G2-044
Experimental
capsule
干预措施: NP-G2-044 (Drug)
结局指标
主要结局
Establish the safe recommended phase 2 dose
时间窗: 24 months
Treatment related adverse events assessed by CTCAE V4.03
次要结局
- Tmax(24 months)
- Cmax(24 months)
- Identify and characterize preliminary anti tumor activity(24 months)
- Characterize the pharmacokinetics of NP-G2-044(24 months)
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungColorectal CancerNCT05397171AstraZeneca17
招募中
1 期
Clinical Trial of BT02 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT06404905Cancer Institute and Hospital, Chinese Academy of Medical Sciences60
终止
1 期
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneMultiple MyelomaNCT04075721EMD Serono Research & Development Institute, Inc.10
招募中
1 期
Study of BC3195 Monotherapy in Patients With Advanced Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT05957471Biocity Biopharmaceutics Co., Ltd.27
终止
1 期
Study of 23ME-01473 in Patients With Advanced Solid MalignanciesSolid TumorNCT0629038823andMe, Inc.5